4.2 Review

Alpha-fetoprotein, a fascinating protein and biomarker in neurology

期刊

EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY
卷 18, 期 3, 页码 243-248

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.ejpn.2013.09.003

关键词

Alpha-fetoprotein (AFP); Diagnostic biomarker; AFP deficiency; Hereditary persistence of AFP; Ataxia Telangiectasia; Ataxia with oculomotor apraxia type 1 and 2; Mitochondrial disorders

向作者/读者索取更多资源

Alpha-fetoprotein (AFP) is present in fetal serum in concentrations up to 5,000,000 mu g/l. After birth, AFP gene expression is turned down with a subsequent fall of the serum concentrations of this albumin-like protein to 'adult values' of circa 0.5-15 mu g/l from the age of 2 years onwards. Irrespective of its assumed important functions, individuals with AFP deficiency appear fully healthy. The other way around, the presence of AFP in the circulation after the first years of life doesn't seem to harm, since individuals with 'hereditary persistence of AFP' are also without clinical abnormalities. During pregnancy, AFP (in maternal serum) has long been recognized as a marker for congenital anomalies of the fetus. Equally well known is AFP as biomarker for hepatocellular carcinoma and some other malignancies. There are at least four neurodegenerative disorders, all inherited as autosomal recessive traits and characterized by the presence of cerebellar ataxia, abnormal ocular movements, and neuropathy, for which an elevated concentration of serum AFP is an important diagnostic biomarker. The availability of a reliable biomarker is not only important during screening or diagnostic processes, but is also relevant for objective follow-up during (future) therapeutic interventions. (C) 2013 Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Endocrinology & Metabolism

Disturbed brain ether lipid metabolism and histology inSjogren-Larssonsyndrome

Pippa Staps, William B. Rizzo, Frederic M. Vaz, Marianna Bugiani, Martin Giera, Bram Heijs, Antoine H. C. van Kampen, Mia L. Pras-Raves, Marjolein Breur, Annemieke Groen, Sacha Ferdinandusse, Marinette van der Graaf, Gert Van Goethem, Martin Lammens, Ron A. Wevers, Michel A. A. P. Willemsen

JOURNAL OF INHERITED METABOLIC DISEASE (2020)

Article Genetics & Heredity

The membrane protein ANKH is crucial for bone mechanical performance by mediating cellular export of citrate and ATP

Flora Szeri, Stefan Lundkvist, Sylvia Donnelly, Udo F. H. Engelke, Kyu Rhee, Charlene J. Williams, John P. Sundberg, Ron A. Wevers, Ryan E. Tomlinson, Robert S. Jansen, Koen van de Wetering

PLOS GENETICS (2020)

Article Genetics & Heredity

metPropagate: network-guided propagation of metabolomic information for prioritization of metabolic disease genes

Emma J. Graham Linck, Phillip A. Richmond, Maja Tarailo-Graovac, Udo Engelke, Leo A. J. Kluijtmans, Karlien L. M. Coene, Ron A. Wevers, Wyeth Wasserman, Clara D. M. van Karnebeek, Sara Mostafavi

NPJ GENOMIC MEDICINE (2020)

Article Genetics & Heredity

Expanding the clinical and genetic spectrum of CAD deficiency: an epileptic encephalopathy treatable with uridine supplementation

Daisy Rymen, Martijn Lindhout, Maria Spanou, Farah Ashrafzadeh, Ira Benkel, Cornelia Betzler, Christine Coubes, Hans Hartmann, Julie D. Kaplan, Diana Ballhausen, Johannes Koch, Jan Lotte, Mohammad Hasan Mohammadi, Marianne Rohrbach, Argirios Dinopoulos, Marieke Wermuth, Daniel Willis, Karin Brugger, Ron A. Wevers, Eugen Boltshauser, Jorgen Bierau, Johannes A. Mayr, Saskia B. Wortmann

GENETICS IN MEDICINE (2020)

Review Endocrinology & Metabolism

Clinical presentation and long-term follow-up of dopamine beta hydroxylase deficiency

Tessa Wassenberg, Jaap Deinum, Frans J. van Ittersum, Erik-Jan Kamsteeg, Maartje Pennings, Marcel M. Verbeek, Ron A. Wevers, Mirjam E. van Albada, Ido P. Kema, Jorie Versmissen, Ton van den Meiracker, Jacques W. M. Lenders, Leo Monnens, Michel A. Willemsen

Summary: DBH deficiency is a rare genetic disorder characterized by severe orthostatic hypotension, which can be treated with L-DOPS. Patients show significant improvement with L-DOPS treatment, but orthostatic hypotension, renal function, anemia, and hypomagnesemia remain partially resolved.

JOURNAL OF INHERITED METABOLIC DISEASE (2021)

Article Biochemistry & Molecular Biology

Evaluation of cyclooxygenase oxylipins as potential biomarker for obesity- associated adipose tissue inflammation and type 2 diabetes using targeted multiple reaction monitoring mass spectrometry

Roel Tans, Rieke Bande, Arno van Rooij, Billy J. Molloy, Rinke Stienstra, Cees J. Tack, Ron A. Wevers, Hans J. C. T. Wessels, Jolein Gloerich, Alain J. van Gool

PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS (2020)

Article Neurosciences

Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase

Anouke van Rumund, Lukas Pavelka, Rianne A. J. Esselink, Ben P. M. Geurtz, Ron A. Wevers, Brit Mollenhauer, Rejko Krueger, Bastiaan R. Bloem, Marcel M. Verbeek

Summary: The study found that Parkinson's disease patients using peripheral decarboxylase inhibitors had elevated serum AADC enzyme activity, which may lead to the need for increased levodopa dosage to maintain therapeutic effects.

NPJ PARKINSONS DISEASE (2021)

Article Biology

Amadori rearrangement products as potential biomarkers for inborn errors of amino-acid metabolism

Rianne E. van Outersterp, Sam J. Moons, Udo F. H. Engelke, Herman Bentlage, Tessa M. A. Peters, Arno van Rooij, Marleen C. D. G. Huigen, Siebolt de Boer, Ed van der Heeft, Leo A. J. Kluijtmans, Clara D. M. van Karnebeek, Ron A. Wevers, Giel Berden, Jos Oomens, Thomas J. Boltje, Karlien L. M. Coene, Jonathan Martens

Summary: The identification of disease biomarkers is crucial for diagnosing inborn errors of metabolism and understanding their pathophysiology. Research has found a class of Amadori rearrangement products that may serve as potential biomarkers for certain metabolic disorders.

COMMUNICATIONS BIOLOGY (2021)

Correction Genetics & Heredity

Neutropenia and intellectual disability are hallmarks of biallelic and de novo CLPB deficiency (Jun, 10.1038/s41436-021-01194-x, 2021)

Saskia B. Wortmann, Szymon Zietkiewicz, Sergio Guerrero-Castillo, Rene G. Feichtinger, Matias Wagner, Jacqui Russell, Carolyn Ellaway, Dagmara Mroz, Hubert Wyszkowski, Denisa Weis, Iris Hannibal, Celina von Stulpnagel, Alfredo Cabrera-Orefice, Uta Lichter-Konecki, Jenna Gaesser, Randy Windreich, Kasiani C. Myers, Robert Lorsbach, Russell C. Dale, Soren Gersting, Carlos E. Prada, John Christodoulou, Nicole I. Wolf, Hanka Venselaar, Johannes A. Mayr, Ron A. Wevers

GENETICS IN MEDICINE (2021)

Article Genetics & Heredity

Neutropenia and intellectual disability are hallmarks of biallelic and de novo CLPB deficiency

Saskia B. Wortmann, Szymon Zietkiewicz, Sergio Guerrero-Castillo, Rene G. Feichtinger, Matias Wagner, Jacqui Russell, Carolyn Ellaway, Dagmara Mroz, Hubert Wyszkowski, Denisa Weis, Iris Hannibal, Celina von Stuelpnagel, Alfredo Cabrera-Orefice, Uta Lichter-Konecki, Jenna Gaesser, Randy Windreich, Kasiani C. Myers, Robert Lorsbach, Russell C. Dale, Soren Gersting, Carlos E. Prada, John Christodoulou, Nicole I. Wolf, Hanka Venselaar, Johannes A. Mayr, Ron A. Wevers

Summary: This study investigated monoallelic CLPB variants in patients with a phenotype dominated by epilepsy, developmental issues, and 3-methylglutaconic aciduria. The results showed that these variants disrupt the refoldase and ATPase activity of CLPB, leading to a phenotypic spectrum centered around neurodevelopmental delay, seizures, and neutropenia, presumably mediated via HAX1.

GENETICS IN MEDICINE (2021)

Article Genetics & Heredity

Blood, urine and cerebrospinal fluid analysis in TH and AADC deficiency and the effect of treatment

Tessa Wassenberg, Ben P. H. Geurtz, Leo Monnens, Ron A. Wevers, Michel A. Willemsen, Marcel M. Verbeek

Summary: This study confirms that cerebrospinal fluid is the most informative body fluid to measure monoamine neurotransmitter metabolites when AADC or TH deficiency is suspected, and that routine follow-up of cerebrospinal fluid measurements to estimate treatment response is not needed. 3-O-methyldopa in dried blood spots and vanillactic acid in urine are promising peripheral biomarkers for diagnosis of AADC deficiency. However, in many patients with TH or AADC deficiency dopamine in urine is normal or increased thereby not reflecting the metabolic block. The value of serum prolactin for follow-up of AADC and TH deficiency should be further studied.

MOLECULAR GENETICS AND METABOLISM REPORTS (2021)

Article Biochemistry & Molecular Biology

Preanalytical Pitfalls in Untargeted Plasma Nuclear Magnetic Resonance Metabolomics of Endocrine Hypertension

Nikolaos G. Bliziotis, Leo A. J. Kluijtmans, Gerjen H. Tinnevelt, Parminder Reel, Smarti Reel, Katharina Langton, Mercedes Robledo, Christina Pamporaki, Alessio Pecori, Josie Van Kralingen, Martina Tetti, Udo F. H. Engelke, Zoran Erlic, Jasper Engel, Timo Deutschbein, Svenja Noelting, Aleksander Prejbisz, Susan Richter, Jerzy Adamski, Andrzej Januszewicz, Filippo Ceccato, Carla Scaroni, Michael C. Dennedy, Tracy A. Williams, Livia Lenzini, Anne-Paule Gimenez-Roqueplo, Eleanor Davies, Martin Fassnacht, Hanna Remde, Graeme Eisenhofer, Felix Beuschlein, Matthias Kroiss, Emily Jefferson, Maria-Christina Zennaro, Ron A. Wevers, Jeroen J. Jansen, Jaap Deinum, Henri J. L. M. Timmers

Summary: This study aimed to establish signatures for different forms of endocrine hypertension (EHT) and investigate unbiased disease biomarkers. Plasma samples from 13 biobanks across seven countries were analyzed using untargeted NMR metabolomics. While signatures that could differentiate different forms of EHT were found, confounding effects related to sample center and age were also identified. Various approaches were applied to correct these confounding effects, but no biomarkers for differentiating primary hypertension from EHT could be identified.

METABOLITES (2022)

Article Biochemistry & Molecular Biology

PPA1 Deficiency Causes a Deranged Galactose Metabolism Recognizable in Neonatal Screening

Melanie T. Achleitner, Judith J. M. Jans, Laura Ebner, Johannes Spenger, Vassiliki Konstantopoulou, Rene G. Feichtinger, Karin Brugger, Doris Mayr, Ron A. Wevers, Christian Thiel, Saskia B. Wortmann, Johannes A. Mayr

Summary: Two siblings showed increased levels of galactose and related metabolites in neonatal screening, but diagnostic tests did not identify abnormalities in known disease-causing enzymes. Whole-exome sequencing revealed a homozygous missense variant in the PPA1 gene, which was found to reduce enzyme activity and protein stability. The observed metabolic derangement is hypothesized to be a mild manifestation of PPA1 deficiency.

METABOLITES (2023)

Correction Biochemistry & Molecular Biology

A framework for evaluating long-term impact of newborn screening ( oct , 2023 , 10.1038/s41431-023-01469-8)

Shona Kalkman, Ron A. Wevers, Frits A. Wijburg, Mariska M. G. Leeflang

EUROPEAN JOURNAL OF HUMAN GENETICS (2023)

Article Biochemistry & Molecular Biology

Metabolomics-Based Screening of Inborn Errors of Metabolism: Enhancing Clinical Application with a Robust Computational Pipeline

Brechtje Hoegen, Alan Zammit, Albert Gerritsen, Udo F. H. Engelke, Steven Castelein, Maartje van de Vorst, Leo A. J. Kluijtmans, Marleen C. D. G. Huigen, Ron A. Wevers, Alain J. van Gool, Christian Gilissen, Karlien L. M. Coene, Purva Kulkarni

Summary: Inborn errors of metabolism are genetic diseases caused by defects in enzymes or cofactors, with untargeted metabolomics serving as a high throughput method for diagnostic screening. However, the complexity of metabolomics data poses a challenge for clinical applications.

METABOLITES (2021)

Article Clinical Neurology

Respiratory function in LAMA2-related muscular dystrophy and SELENON-related congenital myopathy, a 1.5-year natural history study

Karlijn Bouman, Jeroen L. M. van Doorn, Jan T. Groothuis, Peter J. Wijkstra, Baziel G. M. van Engelen, Corrie E. Erasmus, Jonne Doorduin, Nicol C. Voermans

Summary: The majority of LAMA2-MD and all SELENON-RM patients had respiratory impairment. SELENON-RM patients showed lower respiratory function which was progressive, more prevalent mechanical ventilation, and more severe diaphragm atrophy and dysfunction than LAMA2-MD patients. Spirometry (FVC%, dVC) and respiratory muscle strength tests (SNIP) are useful in clinical care and as outcome measure in clinical trials.

EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2024)

Article Clinical Neurology

An online survey among general pediatricians on melatonin use in children with chronic insomnia

Oliviero Bruni, Maria Breda, Emanuela Malorgio, Paolo Brambilla, Flavia Ceschin, Andrea Di Pilla, Maurizio Elia, Raffaele Ferri

Summary: This study aimed to describe the use of melatonin by Italian pediatricians in healthy children with chronic insomnia. The results showed that a high percentage of pediatricians prescribed melatonin, especially in children aged 1-2 years. The most common dosage was 1 mg/day and it was usually recommended to be taken 30 minutes before bedtime. Melatonin was often combined with sleep hygiene and was found to be effective in reducing difficulties falling asleep.

EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2024)

Article Clinical Neurology

Yield of exome sequencing in patients with developmental and epileptic encephalopathies and inconclusive targeted gene panel

Lucie Sedlackova, Katalin Sterbova, Marketa Vlckova, Pavel Seeman, Jana Zarubova, Petr Marusic, Pavel Krsek, Hana Krijtova, Alena Musilova, Petra Lassuthova

Summary: In this study, whole exome sequencing (WES) was performed to identify causal variants for developmental and epileptic encephalopathies (DEEs) in patients whose genetic diagnosis was not determined by gene panel testing. The results showed that WES can successfully identify disease-causing variants, even after inconclusive gene panel testing. Detailed clinical evaluations and phenotype-genotype correlation studies were conducted to better understand the rare subtypes of DEEs.

EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2024)